APLT Applied Therapeutics Inc
1,161
$4.04
$0.14
(3.35%)
| Watchers | 1,161 |
| 52-Wk Low | $1.18 |
| 52-Wk High | $9.39 |
| Market Cap | $461.64M |
| Volume | 524,910.00 |
| 52-Wk High | $9.39 |
| 52-Wk Low | $1.18 |
Applied Therapeutics to present data from study of caficrestat in DbCMThe Fly • about 2 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 3,790,000 shares...
U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday.
read more...
Royal Bank of Canada assumed coverage on shares of Applied Therapeutics (NASDAQ:APLT Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage...
Applied Therapeutics gets extension of FDA review for rare disease drug...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
This indicator may be signaling APLT's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...